Recently, a groundbreaking therapeutic strategy utilizing molybdenum disulfide (MoS2) as a carrier for the delivery of anti-PD-L1 antibody and V9302, a competitive transmembrane antagonist targeting the amino acid transporter ASCT2, has demonstrated remarkable potential in enhancing anti-tumor immune responses within TNBC cells [194]. Here, CD274 is linked to neoplasm.